<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 303 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page302.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=303">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 303 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 303</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=303"><img src="../thumb/303.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>266 / 2020-04                                                            Anti-Microbials - 18.12
   next dos.but take next dos. ASAP. Supplem.addit.200 mg in adult   poss benefic., concom.didanosine not recomm.esp.where vir loads   Drug interactions: Reduc.NNRTI conc.with St John’s Wort expect.,
   pts.with ren. dysfunct.undergo.haemodialys.  high and CD4 cell counts low, HIV transmiss.risk not prev., high. vi-  addit.CNS effs.with alcoh./ psychoact.meds., alt.plasma conc.of
   HIV-1 infect: Adults: Init.200 mg dly.x14 days (ie lead-in period) foll.  rologic. fail.& early emerg.resist.report.when combin. with once dly.  meds.prim. metab.by cytochrome P450 isoenzym., rifampicin decr.
   by 200 mg 2xdly.in combinat. with at least two antiretrov.agents.   lamivudine/abacavir & lamivudine/didanosine regimens, concom.   efavirenz conc., clarithromyc.plasma lev.decr., efavirenz reduc.vori-
   Paed: 2 mnths.-8 yrs: Recomm.dos: 4 mg/kg 1xdly.for 2 wks.foll.  atazanavir without ritonavir not recomm., discont. concom.didano-  conazole plasma conc.& vice versa, amprenavir./atazanavir/indina-
   by 7 mg/kg 2xdly. 8 yrs.& old: 4 mg/kg 1xdly for 2 wks.foll.by 4 mg/  sine if didanosine advers. effs. develop.  vir/lopinavir & saquinavir ser.conc decr., efavirenz metabol. inhibit. by
   kg 2xdly. Tot.dly.dos. not to exceed.400 mg for any pt.  Drug interactions: Ser.conc.of drugs elimin.by act.tubul.secret.  grapefruit juice, conc.of drugs reduc.ren. funct./elimin.by act.tubul.
   Adults & Childr.(50 kg/more bm) able to swallow tabs.admin.200mg   may incr., AUC & C min of atazanavir decr., AUC of didanosine incr.,   secret.may be incr., atazanavir & lopinavir/ritonavir incr.tenofovir
   tabs.instead.                AUC incr.with lopinavir/ritonavir combinat., ser.conc.incr.by agents   conc., reduc.anticonvuls.&/efavirenz.plasma lev. with carbamaz-
   Contraindications: Sev.hepat.dysfunct., Child-Pugh class B or   reduc.ren.funct.  epine/phenytoin & phenobarbit., sertraline conc.decr., HMG-CoA
   C, end-stage ren.fail.in pts.not on haemodialys., pre-treatm./dur.  CIPLAFAM, Cipla Medpro [P/S]  reduct.inhibit./ indinavir/ itraconazole conc.decr., potent.decr. keto-
   treatm.values of AST/ALT&gt; 5x ULN until AST/ALT stabilis.&lt; 5x ULN.,   conazole conc., rifabutin conc.decr., plasma conc.of other compds.
   re-admin.in cases of sev.rash/rash with constitut. sympts./hypers-  Famciclovir  that are CYP3A4 substrat. poss.decr., poss.Ca chan.block.conc.decr.,
                                Indications: Herpes zoster (shingles) infect., 1st episode genit.
   ens.syndr./if ther.discont. for clinic.hepatit., AST/ALTvalues &gt; 5x ULN   decr. methadone plasma conc.& poss.opiate withdr. signs with efa-
   dur. ther. & had rapid recurr.of liv.funct.abnormalit. on re-admin.,   herpes within 72 hrs.of sympts, recurr. genit.herpes within 6 hrs.  virenz, ethinyl oestrad.conc.incr.
                                of sympts, suppress. recurr. genital herpes in immunocompet. pts.
   safety in pregn.& lactat.not est., concom. ketoconazole/rifampicin
   & St. John’s Wort, not stud.in ren./hepat.dysfunct.  (S4) TABS, 42/20.2.8/0667, 0668  COMBIVIR, GSK [P/S]
                                718876-001: 125 mg, 10, R135,70
                                                              Lamivudine 150 mg, zidovudine 300 mg
   Side effects: Sev.& life threaten.skin reacts. incl. Stevens-Johnson
   & tox.epiderm.necrolys., hypersens. syndr., constitut.finds.& visceral   718877-001: 250 mg, 21, R592,25  Indications: Part of anti-retroviral combinat.ther. for treatm.of HIV
                                                              infect.pts.with progress. immunodefic., init.prophylax.(unt.serology
                                Dosage: Herpes zoster: Adults: 250 mg 3xdly.x7 days. Init.within
   involvem., sev.& life threaten.hepatotox.incl.fatal fulmin. hepatit.&   72 hrs of rash onset.  test results avail.) in HIV neg.adults follow.occupat. expos.
   hepat.fail., cutan.reacts.(see lit. for detail.descript.), somnol., bld.  1st episode genital herpes: Within 72 hrs of appear. of   (S4) TABS, 32/20.2.8/0705
   dyscras., allerg. reacts., hypersens.syndr., anaphylax., headache,   sympts.250 mg 3xdly.x5 days.  875821-006: 60, R577,88
   GI disturbs., jaund., skin & subcutan.disords., angioed., myalg., ar-  Recurr.genital herpes: Within 6 hrs of sympts appear., 125 mg   Dosage: Consult P/I for dos.if used in combin.with anoth.anti-
   thralg., fatig., fev., lymphadenopathy, ren.dysfunct., pancreatit., lipo-  2xdly.x5 days.  viral agent.
   dystrophy, periph.neuropathy, granulocytop. more common in childr.  Suppress.recurr.genital infects.in immunocompet. pts: 125-  Adults & adolesc. weigh.at least 30 kg: Recomm.1 tab 2x dly.
   Special precautions: Always admin.in combinat. with at least 2   250 mg 2xdly., treatm. durat.dep.on sever. Re-eval.treatm.aft.12   Childr. 21-30 kg: Recomm. ½ tab in morn. & 1 tab in even. Childr.
   addit.antiretrovir.agents as in monother. resist.virus.emerge rapid.,   mnths. Max.toler. dos: Herpes zoster: 750 mg 3x/day for 7 days. Gen-  14-21 kg: Recomm.½ tab 2x dly. Childr.weigh. less than 14 kg:
   freq. observ. pts with pretreatm.AST/ALT of 2-3x ULN dur.early   it.herpes: 750 mg 3x dly.for 5 days & up to 500 mg 3x/day for 10 days.  Lamuvidine & zidovudine to be taken as separ.formulat.
   treatm.period for developm.clinic./lab.evid.liv. funct.deteriorat.,   Contraindications: Penciclovir hypersens., pregn. & lactat., safety   Post expos.prophylax: Init.ther. pref.with.1-2 hrs aft. expos. Cont.
   adeq.contracept., 1  18 wks.ther. critic.to monit.for sev.& life-threat.  & effic. in childr.not est.  unt.confirm.of HIV status of source. Prophylact.course to be contin.
           st
   skin reacts.& ser.hepatit./ hepat.fail., great.risk of hepat.events &   Side effects: Psych./CNS effs., headache, dizzin., GI disturbs.,   for 4 wks should source be confirm.as HIV pos. Dos: 1 tab 2x dly.for
   skin reacts.occur.1  6 wks.ther., women CD4 + &gt;250, men CD4 + &gt;   jaund., skin reacts.  28 days. Dos.to be strict.adher.to. Discont. ther.as soon as source
           st
   400 counts incr.risk hepat. adverse events, dos.esp.14 day lead in   Special precautions: Elderly, imp.ren.funct., transmiss.risk of   is confirm.not to be HIV infect.
   period to be strict. adher.to, risk fact.for develop.ser.cutan. reacts.   genit. herpes incr.dur. ac.episod., avoid intercourse while sympt.  Contra-indications: Abnorm.low neutrophil counts/ haemoglob.
   incl.fail.to foll.init.dos.of 200 mg dur.lead-in period, dos.escalat.not   pres., adeq protect. dur. intercourse., lact.intol.  lev., childr.weigh.less than 14 kg, concom.stavudine/zalcitabine,
   allow.if rash occur.dur lead-in dos.until rash.resolv., perman.discont.  Drug interactions: Probenecid & other drugs that aff.ren.physiol.  safety in pregn.not est., lactat., concom.IV ganciclovir/ foscarnet
   ther. in pts experic.sev.rash/rash with constitut.sympts./ in case of   could aff.plasma lev.  not recomm.
   hypersens.syndr.& visceral involvem., long delay betw.init.sympts.&   Side-effects: Bld.dyscras., pure red cell aplas., aplast.anaem.,
   medic.cons.may incr.risk of more ser.cutan.reacts., women at high.   CITENVIR, Novagen [P/S]  pancreatit., lact.acidos.& sev. hepatomegaly with steatos.incl.fa-
   risk than men of rash dev., ther.assoc.rash perform liv.funct. test.im-  Efavirenz 600 mg, emtricitabine 200 mg, tenofovir disoproxil fu-  talit. esp. women, hyperlactataem., headache, paraesth., periph.
   med., perman.discont.ther.in pts. with mod.to sev. elevat.(AST/ALT   marate 300 mg.  neuropathy, cough, nas.sympts., GI disturbs., rash, alopec., arthralg.,
   &gt;5 x ULN), incr. AST/ALT lev.and/or chron.hepatit.B&C co-infect. prior   Indications: HIV-1 infect.treatm.in adults alone as complete regi-  musculoskelet. pain, rhabdomyolys., fatig., malaise, fev., anx., de-
   to ther.is assoc.with great.risk of hepat. adverse events dur. antiret-  men or in combination with other anti-retrovir.  press., dizzin., CNS effs., convuls., cardiomyopathy, dyspn., nail,skin
               st
   rovir.ther.in gen., pts.to report.1  sympts of hepatit.to dr.immed., con-  (S4) TABS, 47/20.2.8/0504  & oral mucosa pigmentat., taste disturbs., dyspeps., skin reacts.,
   com. antivir. ther.for hepatit.B & C refer relev.medic. product info of   718874-001: 30, R488,12  sweat., myalg., myopathy, urin.freq., gynaecomast., asthen., chest
   products, opportunist.infects.& other complicat.of HIV infect.may   Dosage: Adults: 1 tab.once dly.on empty stomach. Bedt.dos.may   & gen.pain, chills, flu-like syndr.
   contin., monit. liv. funct.prior to & at interv.dur.ther., interupt.ther.   improv.CNS sympt. tolerabil.  Special precautions: Developm.of opportunist. infects.& other
   in case of mod./sev.abnorm.liv.funct.tests & only re-introd.at init.   Contraindications: Concur.astemizole/bepridil/ cisapride/ mida-  HIV complic.poss.cont., ther.not prov.to prev.HIV transmiss.risk,
   dos.once tests return.to baseline, concom.flucoconazole/warfar.,   zolam/pimozide/triazolam/ergot derivat.& voriconazole, mod-sev.  monit.haematolog. paramet., discont.ther.immed.if pancreatit.susp.,
   consid.decr. concom. rifabutin dos., alt.ther.to clarithromycin recom.   ren.impairm., safety & effic. not est.in HBV & HIV co-infects., con-  known risk fact.for liv.dis., suspend ther.if clinic./ lab.find.suggest.of
   in Mycobacterium avium-intracellular complex., maj.toxic.is skin   com. lamivudine/meds.contain.lamivudine in combinat., concom.  lact.acidos./hepatotoxic., body fat redistribut./accumulat., immune
   rash notify dr.immed., if ther.interrupt.for long.than 7 days restart   St Johns Wort not recomm., safety & effic.in pts.less than 18 yrs.  reconstit. syndr. when ther.init., co-infect.with Hepatit.C virus, cross.
   with lead-in dos., ther.not a cure, monit.methadone maint. pts.as   not est., concom. atazanavir/saquinavir not recomm., pregn., lac-  placenta in animal studies, carcinogen. risk, in pregn.only if benef.
   narcot.withdr.syndr. report.  tat., sev.hepat.impairm.     outweighs poss.risk, pass.into breast milk, elderly, ren.impairm.,
                   st
   Drug interactions: Incr.in rash dur.1  6 wks.of ther. assoc.with   Side effects: Lactic.acidos.& sev.hepatomegaly with steatos.  sev.hepat. impairm., where dos.adjustm.necess. use separ.preps.,
   concom.prednisone, poss.decr.in plasma conc.of other concom.  incl.fatal.esp.in women, sev.ac. exacerbat. of hepatit.B aft.discon-  self-admin.medicat., advanc. cirrhot. liv.dis.due to chron.Hepat.B in-
   admin.meds.extens., low.plasma conc.of concom.meds.metabol.  tinuat.of emtricitabine/ tenofovir, ser.CNS & psych.sympts., poss.   fect., poss. rebound hepatit.risk, haematolog.adverse reacts., bld.
   by CYP3A or CYP2B enzymes, saquinavir (hard gelatine caps) &   birth defects, pancreatit., rais.ser.cholestrol & triglycer.conc., sev.  tests recomm.2 wkly for 1  3 mnths & thereaft. at least mnthly.,
                                                                         st
   indinavir AUC lev.reduc., AUC, C max & C minsignific.low.by rifampicin,   depress., suicid.ideat./ attempts, amnes., aggress., mania, tinnit.,   monit.with concom.co-trimoxazole, concom.clarithromycin/pheny-
   rifabutin conc. signific.incr., hypericum perfortum (St John’s Wort)   palpitat., dyspn., GI disturbs., rais.liv.enzym., hepat. fail., rash, pru-  toin, monit. pts.on prolong.atovaquone ther., concom. agents alter.
   decr.NNRTI’s conc.& result.sub-optimal lev., elev. trough conc.with   rit., erythem.multiforme/nail disords. /Stev.-John.syndr., photo allerg.  zidovudine metabol.esp.in chron.ther., concom. potent.nephrotox./
   cimetidine, plasma conc.of methadone decr., oestrog.lev.of OC’s   dermatit., skin discol., arthralg., myalg., myopathy, fatig., asthen.,   myelosuppress.agents, concom. prophylact.antimicrob.ther.in contin.
   signific. decr., ketoconazole & erythromycin signific.inhibit. format.  pneum., neutropen., anaem., hyperbilirubinaem., abnorm.dreams,   opportunist.infects., elev.ser.lact.lev., discont. Combivir & use separ.
   of hydroxylated metabol., warfar may incr./ decr.coagulat.time, AUC   headache, asthen., dizzin., insom., anx., paraesthes., periph. neu-  zivodine/lamivudine preps. if sympt.sev.
   & C max of ketoconazole signif. reduc.& nevirapine plasma lev.incr.,   ropathy, rhinit., pain, hypophosphataem., bone pain, osteomalac.,   Drug interactions: Trimethoprim incr.plasma lev., lamuvidine
   fluconazole incr nevirapine expos.  nephrit., nephrogen.diabet. insipid., ren.proxim.tubul.eff.incl.Fanconi   poss.inhib. zalcitabine intracell. phosphorylat., reduc.absorpt.with
                                syndr.& ac.tubul.necros., ac.ren.fail., sinusit., URTI, nasopharangit.,
   CIPLA TENOFOVIR 300, Cipla Medpro [P/S]  immune reconstitut.syndr., Cushingoid appear., redistribut./accumu-  clarithromycin, zivodine AUC decr.with concom.rifampicin, poss. decr.
                                                              zivodine metabol.rate with atovaquone, alt. bld.lev.with phenytoin,
   Tenofovir disoproxil fumarate  lat.of body fat, hyperglyceridaem., insul.resist., breast enlargem.,
   Indications: In combinat.with other antiretrovir.in adults over 18   periph.& fac.wast., hyperton., myosit., rhabdomyolys., osteone-  probenecid incr.mean half-life & AUC of zidovudine., stavudine intra-
                                                              cell. phosphorylat.poss.inhib.by zidovudine, incr.incid.of neutropen.
   yrs.with HIV-1 infect.       cros., reduc.bone density.
   (S4) TABS, 42/20.2.8/0561    Special precautions: Monit.hepat.funct.for sev. mnths. in pts.  with paracet., cert.agents incl.aspir./ morph./ lorazepam /naprox./
                                                              cimetidine/clofibrate poss.alt. zidovudine metabol.by inhib. glucoro-
   714097-001: 300 mg, 30, R162,15  co-infect.with HIV & HBV who discont. ther.& appropr.init.of anti-  nidat. /direct. inhibit.hepat.microsom. metabol.
   Dosage: 300 mg once dly.with food.  hepatit.B ther. poss.necess., obesity & prolong.nucleoside use poss.
   Contra-indications: Safety & effic.not est.in hepatit. B vir.co-in-  risk fact.for lact.acidos., liv.dis.risk fact., discont. if find.suggest.lact.  COMBOZIL,(Activo) Hetero [P/S]
   fects., mod.to sev.ren.impairm., pregn. & breast feed., not recomm.  acidos./hepatotoxic., test for chron.hepatit.B bef.init.ther., monit.  Lamivudine 150 mg, zidovudine 300 mg
   in childr.und.18 yrs.        for hepatit.exacerbat.if treatm.discont.in HIV & HBV co-infect.pts.,   Indications: Part of anti-retroviral combinat.ther. for treatm.of HIV
   Side-effects: Lactic.acidos.& sev.hepatomegaly with steatos.incl.  treatm.discont.poss.reqd.if ser. psych. sympt.exper., determ. crea-  infect.adults & childr.over 12 yrs. with progress.immunodefic. , init.
   fatal., sev.ac.exacerbat.of hepatit. B aft.discontinuat., hypophos-  tin.clear.bef.init. & dur.ther., ren.funct.monit.in pts.at risk/hist.of   prophylax.(unt. serology test results avail.) in HIV neg.adults follow.
   phataem., lipodystrophy, osteonecros., BMD decr., allerg. reacts.,   ren. dysfunct., avoid with concom./ rec.nephrotox. agents, elderly,   suspect./known HIV occupat.expos. Admin. of protease inhibit.
   asthen., headache, depress., insomn., dizzin., periph.neuropathy,   rash report.with efavirenz & clarithromycin theref.consid.alt., poss.  recomm.when large vol.of innoculat. occurs/when source mat.has
   anx., dyspn., pneumon., GI disturbs., pancreatit., hepatit., rash, my-  incr. didanosine-relat.adverse eff., high.freq.adverse events with   high viral titre or when innoculat.occurs from pt.with HIV resist. to
   opathy, osteomalacia, abdom./back/chest pain, arthralg., myalg.,   efavirenz/ritonavir, monit. liv.enzym. with efavirenz/ritonavir, do   zidovudine/lamivudine.
   ren.impairm.incl.ac.ren.fail., nephrit., nephrogen.diabet.insipid.,   not admin.concom. saquinavir as sole protease inhibit., reg. car-  (S4) TABS, 43/20.2.8/0362
   pain, fev., incr. triglycerides.  bamazepine lev.monit.with concom.use, altern. anticonvuls.agent   715669-001, 60, R452,51
   Special precautions: Pts.partic.obese women with hepatomeg-  advis., Ca chann.blocks.dos. adjustm.guid.by clinic.respons., women   Dosage: Adults & childr.over 12 yrs: 1 tab. 2xdly. Consult pack-
   aly/hepatit or other known liv.dis. & hepat.steatos.risk fact., spec.  of child-bear.potent.should undergo pregn.test.bef. init. ther., barr.  age insert for separ.agents admin.dur.combin.ther.
   risk assoc.with hepatit.C co-infect.pts.treat.with alpha-interferon   contracept.tog.with other methods recomm., pt.on treatm.may   Post expos.prophylax: Init.ther. pref.with.1-2 hrs aft. expos. Cont.
   & ribavirin, elderly, ren.monit.prior to init.ther./ mnthly dur.1  yr.&   devel.opportunist. infect./ other HIV infect.compl., contin. approp.   unt.confirm.of HIV status of source. Prophylact.course to be contin.for
                            st
   quarterly thereaft.& more freq. in at risk pts., concom./rec.nephrotox.  precaut. prevent.HIV transmiss.risk, investig. child. expos. in utero   4 wks should source be confirm.as HIV pos. Dos: 1 tab 2x dly. Dos.
   meds., discont. if find.suggest.metabol./lact.acidos./ hepatotoxic.,   to nucleoside & nucleotide analog. for poss.mitochondr.dysfunct.in   to be strict.adher.to. Discont. ther.as soon as source is confirm.not
   test for hepatit.B bef.init.ther., mitochrond.dysfunct.in HIV negat.in-  case of relev. S&S, liv. enzym.monit.in pts.with mild to mod. liv.dis   to be HIV infect. If protease inhibit.reqd.follow.loc.CDC guidelines.
   fts.expos.in uteroI/post natally theref.clinic.& lab.follow-up recomm.,   & chron. hepatit.B or C, seiz/psych. disord. hist., discont. ther.with   Contraindications: Abnorm.low neutrophil counts /haemoglo-
   inflamm.react.to asymptomat./resid. opportunist.pathog.report.in   sev.skin rash assoc. with blister./desquamat./mucos.involvem.&   bin lev., childr.bel.12 yrs., concom. ribavirin/stavudine.zalcitabine,
   sev.immune defic.HIV infect.pts., monit.BMD in pts.with patholog.  fev., monit. ser.lipids & bld.gluc., bone monit.with bone fract. hist./   concom.IV ganciclovir/foscarnet not recomm., safety in pregn.
   bone fract.hist./at risk of osteopen.where Ca & vit.D supplementat.  risk of osteopen.  not est., lactat.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page302.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page298.html">298</a>&nbsp;&nbsp;&nbsp;<a href="page299.html">299</a>&nbsp;&nbsp;&nbsp;<a href="page300.html">300</a>&nbsp;&nbsp;&nbsp;<a href="page301.html">301</a>&nbsp;&nbsp;&nbsp;<a href="page302.html">302</a>&nbsp;&nbsp;&nbsp;<a href="page303.html">303</a>&nbsp;&nbsp;&nbsp;<a href="page304.html">304</a>&nbsp;&nbsp;&nbsp;<a href="page305.html">305</a>&nbsp;&nbsp;&nbsp;<a href="page306.html">306</a>&nbsp;&nbsp;&nbsp;<a href="page307.html">307</a>&nbsp;&nbsp;&nbsp;<a href="page308.html">308</a>
             </td>
             <td width="35%"><a href="page304.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page304.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
